Praxis Precision Medicines, Inc.

NasdaqGS:PRAX Rapporto sulle azioni

Cap. di mercato: US$1.4b

Praxis Precision Medicines Gestione

Gestione criteri di controllo 4/4

Praxis Precision Medicines Il CEO è Marcio De'Souza, nominato in Apr2020, e ha un mandato di 4.58 anni. la retribuzione annua totale è $ 2.12M, composta da 29.5% di stipendio e 70.5% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.089% delle azioni della società, per un valore di $ 1.27M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.9 anni e 3 anni.

Informazioni chiave

Marcio De'Souza

Amministratore delegato

US$2.1m

Compenso totale

Percentuale dello stipendio del CEO29.5%
Mandato del CEO4.6yrs
Proprietà del CEO0.09%
Durata media del management3.9yrs
Durata media del Consiglio di amministrazione3yrs

Aggiornamenti recenti sulla gestione

Recent updates

Praxis Precision Medicines: Great Price Movement, But Still Not Convinced

Oct 13

We're Hopeful That Praxis Precision Medicines (NASDAQ:PRAX) Will Use Its Cash Wisely

Aug 30
We're Hopeful That Praxis Precision Medicines (NASDAQ:PRAX) Will Use Its Cash Wisely

Companies Like Praxis Precision Medicines (NASDAQ:PRAX) Are In A Position To Invest In Growth

May 14
Companies Like Praxis Precision Medicines (NASDAQ:PRAX) Are In A Position To Invest In Growth

Praxis: 2nd Half 2024 ET Readout Could Lead To U.S. Regulatory Filing

Mar 26

Is There An Opportunity With Praxis Precision Medicines, Inc.'s (NASDAQ:PRAX) 26% Undervaluation?

Feb 27
Is There An Opportunity With Praxis Precision Medicines, Inc.'s (NASDAQ:PRAX) 26% Undervaluation?

Here's Why Praxis Precision Medicines (NASDAQ:PRAX) Must Use Its Cash Wisely

Nov 29
Here's Why Praxis Precision Medicines (NASDAQ:PRAX) Must Use Its Cash Wisely

Can Praxis Precision Medicines (NASDAQ:PRAX) Afford To Invest In Growth?

Aug 14
Can Praxis Precision Medicines (NASDAQ:PRAX) Afford To Invest In Growth?

Can Praxis Precision Medicines (NASDAQ:PRAX) Afford To Invest In Growth?

Feb 10
Can Praxis Precision Medicines (NASDAQ:PRAX) Afford To Invest In Growth?

Here's Why Praxis Precision Medicines (NASDAQ:PRAX) Must Use Its Cash Wisely

Oct 21
Here's Why Praxis Precision Medicines (NASDAQ:PRAX) Must Use Its Cash Wisely

Praxis Precision Medicines GAAP EPS of -$1.32 misses by $0.02

Aug 08

Praxis: MDD Trial Failure May Not Mean An End To Entire Pipeline

Jun 10

We're Keeping An Eye On Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate

May 15
We're Keeping An Eye On Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate

Companies Like Praxis Precision Medicines (NASDAQ:PRAX) Are In A Position To Invest In Growth

Jan 27
Companies Like Praxis Precision Medicines (NASDAQ:PRAX) Are In A Position To Invest In Growth

Praxis Precision Medicines: Genetic Medicines For Neurological Disease

Nov 23

We're Not Very Worried About Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate

Oct 14
We're Not Very Worried About Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate

Praxis' PRAX-562 wins Orphan Drug designation for rare encephalopathy

Apr 30

Companies Like Praxis Precision Medicines (NASDAQ:PRAX) Are In A Position To Invest In Growth

Mar 12
Companies Like Praxis Precision Medicines (NASDAQ:PRAX) Are In A Position To Invest In Growth

Read This Before Selling Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares

Jan 18
Read This Before Selling Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares

Praxis Precision's pediatric epilepsy therapies nab Rare Pediatric and Orphan Drug tags in U.S.

Jan 07

Praxis Precision Medicine plummets 27% on clinical hold on lead drug

Nov 10

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Marcio De'Souza rispetto agli utili di Praxis Precision Medicines?
DataCompenso totaleStipendioGuadagni aziendali
Sep 30 2024n/an/a

-US$151m

Jun 30 2024n/an/a

-US$124m

Mar 31 2024n/an/a

-US$125m

Dec 31 2023US$2mUS$625k

-US$123m

Sep 30 2023n/an/a

-US$138m

Jun 30 2023n/an/a

-US$157m

Mar 31 2023n/an/a

-US$183m

Dec 31 2022US$6mUS$625k

-US$214m

Sep 30 2022n/an/a

-US$231m

Jun 30 2022n/an/a

-US$232m

Mar 31 2022n/an/a

-US$208m

Dec 31 2021US$11mUS$571k

-US$167m

Sep 30 2021n/an/a

-US$135m

Jun 30 2021n/an/a

-US$111m

Mar 31 2021n/an/a

-US$88m

Dec 31 2020US$12mUS$385k

-US$70m

Compensazione vs Mercato: La retribuzione totale di Marcio ($USD 2.12M ) è inferiore alla media delle aziende di dimensioni simili nel mercato US ($USD 5.42M ).

Compensazione vs guadagni: La retribuzione di Marcio è stata coerente con le performance aziendali dell'ultimo anno.


AMMINISTRATORE DELEGATO

Marcio De'Souza (45 yo)

4.6yrs

Mandato

US$2,120,512

Compensazione

Mr. Marcio Silva De'Souza has been President, Chief Executive Officer and Director of Praxis Precision Medicines, Inc. since April 2020. Mr. De'Souza joined the Praxis Precision Medicines, Inc. in April 20...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Marcio De'Souza
President4.6yrsUS$2.12m0.089%
$ 1.3m
Timothy Kelly
CFO & Treasurer3.5yrsUS$1.02m0.019%
$ 272.1k
Alex Nemiroff
General Counsel & Secretary4.4yrsUS$843.11k0.013%
$ 180.7k
Steven Petrou
Co-Founder & Chief Scientific Officer6.8yrsNessun datoNessun dato
Lauren Mastrocola
VP of Finance & Principal Accounting Officerno dataNessun dato0.0085%
$ 122.2k
Karl Hansen
Chief Technical Operations Officer2.9yrsNessun datoNessun dato
Alex Kane
VP of Investor Relations & Corporate Communicationsno dataNessun datoNessun dato
Kelly McCue
Chief People Officer3.9yrsNessun dato0.016%
$ 225.5k
Alyssa J. Wyant
Chief Regulatory & Quality Officer4.2yrsNessun datoNessun dato
Megan Sniecinski
Chief Business Officer2.9yrsNessun datoNessun dato
Brian Spar
Chief of Staff2.7yrsNessun datoNessun dato

3.9yrs

Durata media

45yo

Età media

Gestione esperta: Il team dirigenziale di PRAX è considerato esperto (durata media dell'incarico 3.9 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Marcio De'Souza
President4.6yrsUS$2.12m0.089%
$ 1.3m
William Young
Independent Director7.9yrsUS$79.28k0.010%
$ 145.9k
Dean Mitchell
Independent Chairman of the Board4.2yrsUS$104.37k0.027%
$ 384.4k
Gregory Norden
Independent Director5.7yrsUS$82.87k0.0010%
$ 14.5k
Merit Cudkowicz
Independent Director3.6yrsUS$76.28k0%
$ 0
Jill DeSimone
Independent Director2.5yrsUS$78.87k0.0052%
$ 74.2k
Jeffrey Chodakewitz
Independent Director3.6yrsUS$72.87k0%
$ 0
Anna Greka
Member of Scientific Advisory Board1.8yrsNessun datoNessun dato
Matthew Might
Chairman of the Scientific Advisory Board1.8yrsNessun datoNessun dato
Holger Lerche
Member of Scientific Advisory Board1.8yrsNessun datoNessun dato
Ivan Soltesz
Member of Scientific Advisory Board1.8yrsNessun datoNessun dato
Samuel Berkovic
Member of Scientific Advisory Board1.8yrsNessun datoNessun dato

3.0yrs

Durata media

68yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di PRAX sono considerati esperti (durata media dell'incarico 3 anni).